

Ref:corp.sec/2022-23/BSE/209

Dated:07.07.2022

To,

Bombay Stock Exchange Ltd, Phirojshah Jeejobhoy Towers, 25th Floor, Dalal Street, Mumbai 400 001

Manager-Department of Corporate affairs

Sir,

Sub: Outcome of the Board Meeting with Scrip Code 524703.

A Meeting of the Board of Directors of the Company duly convened on Thursday,07th at 05:00 p.m. and concluded at 5.45 p.m. discussed the following July 2022 business: -

- 1. Considered and Reappointed CMA Shekhar Joshi & Co, Cost Accountants (Registration No. 100448) as Cost Auditor of the Company for the Financial Year 2022-23.
- 2. Approved the 3rd and final tranche conversion of outstanding 8,50,326 equity warrants into 8,50, 326 equity shares at a price of Rs.20.69 /- per share (including a premium of Rs.10.69) from the preferential allottees in accordance with the in-principle approval granted by the BSE on March 25, 2021.

You are requested to kindly take the same on record.

Yours Faithfully,

For Sandu Pharmaceuticals Limited

Pratika Mhambray Company Secretary

mhanbiay (



CIN:L24233GA1985PLC001587